OpenAI has launched Codex for Open Source, offering maintainers six months of free ChatGPT Pro and API credits amid a surge of AI-generated pull requests.
FDA Fast Track designation has been granted to CTx001 for Geographic Atrophy secondary to Age-related Macular Degeneration CTx001 is an investigational AAV-based gene therapy designed to modulate ...
AUSTIN, Texas — A local security company is taking a futuristic approach to public safety, teaming up with an Oregon-based robotics firm to patrol neighborhoods using artificial intelligence.
Contineum Therapeutics has pumped the brakes on two projects, freeing up resources to go full speed ahead in its pursuit of Bristol Myers Squibb in idiopathic pulmonary fibrosis (IPF). The San ...
Soon to be the official tool for managing Python installations on Windows, the new Python Installation Manager picks up where the ‘py’ launcher left off. Python is a first-class citizen on Microsoft ...
Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC). Perioperative nivolumab (NIVO) vs ...
(RTTNews) - Cingulate Inc.(CING), a biopharmaceutical company, Tuesday reported positive results from the Phase 3 pediatric study of its lead drug candidate CTx-1301 for the treatment of Attention ...
CTx-1301 is designed to deliver 3 separate releases of medication at different times and in different ratios. Topline data were announced from a phase 3 trial evaluating CTx-1301 for the treatment of ...
Cingulate Inc. completes FDA Pre-NDA meeting for ADHD drug CTx-1301 and secures $3 million grant for anxiety treatment CTx-2103. Cingulate Inc. announced the successful completion of a Pre-NDA meeting ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The drug was central to a $445 ...
After asset purchase from Travere, Mirum's Ctexli crosses FDA finish line in rare metabolic disorder
A little less than two years after San Francisco’s Mirum Pharmaceuticals ponied up $210 million to acquire Travere Therapeutics’ bile acid portfolio, the deal has paid off with a fresh FDA approval.
The winners of a 10-day hunt for Burmese pythons, which had more than 850 participants from 33 states and Canada collectively removing 195 of the invasive species from south Florida, were announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results